Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Sell
16
MTNB Quote, Financials, Valuation and Earnings
Last price:
$0.78
Seasonality move
:
1.63%
Day range:
$0.73 - $0.80
52-week range:
$0.47 - $3.09
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.74x
P/B ratio:
0.78x
Volume:
20.6K
Avg. volume:
25.1K
1-year change:
41.07%
Market cap:
$5.1M
Revenue:
--
EPS (TTM):
-$3.41
Analysts' Opinion
-
Consensus RatingMatinas BioPharma Holdings, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Matinas BioPharma Holdings, Inc. has an estimated upside of 3697.47% from its current price of $0.79.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.79.
Fair Value
-
According to the consensus of 2 analysts, Matinas BioPharma Holdings, Inc. has 3697.47% upside to fair value with a price target of -- per share.
MTNB vs. S&P 500
-
Over the past 5 trading days, Matinas BioPharma Holdings, Inc. has overperformed the S&P 500 by 5.01% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Matinas BioPharma Holdings, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Matinas BioPharma Holdings, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Matinas BioPharma Holdings, Inc. reported revenues of --.
Earnings Growth
-
Matinas BioPharma Holdings, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Matinas BioPharma Holdings, Inc. reported earnings per share of -$0.40.
Enterprise value:
1.9M
EV / Invested capital:
--
Price / LTM sales:
1.74x
EV / EBIT:
--
EV / Revenue:
0.14x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.21x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$613K
Return On Assets:
-131.71%
Net Income Margin (TTM):
--
Return On Equity:
-199.71%
Return On Invested Capital:
-152.52%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.2M | -- | -- | -- | -- | |
| Gross Profit | $1.2M | -$964K | -$613K | -$243K | -$114K | |
| Operating Income | -$23.4M | -$22M | -$9.4M | -$4.4M | -$1.6M | |
| EBITDA | -$22.4M | -$21M | -$8.8M | -$4.1M | -$1.5M | |
| Diluted EPS | -$4.89 | -$4.56 | -$3.41 | -$0.85 | -$0.40 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $56.5M | $37.1M | $20M | $11.7M | $5.7M | |
| Total Assets | $67M | $47.5M | $29.8M | $20.6M | $9.7M | |
| Current Liabilities | $4.1M | $4.9M | $3.2M | $2.1M | $1.5M | |
| Total Liabilities | $8.7M | $8.9M | $6.6M | $4.8M | $3.2M | |
| Total Equity | $58.3M | $38.6M | $23.2M | $15.8M | $6.5M | |
| Total Debt | $4.8M | $3.7M | $3.1M | $2.3M | $1.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15M | -$17M | -$9M | -$3.5M | -$1.5M | |
| Cash From Investing | $10.2M | $11.7M | $820K | $9.6M | $320K | |
| Cash From Financing | -$10.6K | $9.2M | $3.3M | -$67K | $64K | |
| Free Cash Flow | -$15.3M | -$17M | -$9M | -$3.5M | -$1.5M | |
MTNB
Sector
Market Cap
$5.1M
$28.5M
Price % of 52-Week High
25.57%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-28.28%
-1.33%
1-Year Price Total Return
41.07%
-20.32%
Beta (5-Year)
1.321
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.76
200-day SMA
Sell
Level
$1.08
Bollinger Bands (100)
Sell
Level
1 - 1.88
Chaikin Money Flow
Sell
Level
-12.6M
20-day SMA
Sell
Level
$0.95
Relative Strength Index (RSI14)
Sell
Level
32.47
ADX Line
Sell
Level
47.28
Williams %R
Buy
Level
-83.3333
50-day SMA
Sell
Level
$1.38
MACD (12, 26)
Sell
Level
-0.18
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
46.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-26.5771)
Sell
CA Score
(Annual)
Level (-3.5104)
Buy
Beneish M-Score
(Annual)
Level (-9.2464)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (11.1594)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.
Stock Forecast FAQ
In the current month, MTNB has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The MTNB average analyst price target in the past 3 months is --.
-
Where Will Matinas BioPharma Holdings, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Matinas BioPharma Holdings, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Matinas BioPharma Holdings, Inc.?
Analysts are divided on their view about Matinas BioPharma Holdings, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Matinas BioPharma Holdings, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Matinas BioPharma Holdings, Inc.'s Price Target?
The price target for Matinas BioPharma Holdings, Inc. over the next 1-year time period is forecast to be -- according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is MTNB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Matinas BioPharma Holdings, Inc. is a Hold. 2 of 2 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of MTNB?
You can purchase shares of Matinas BioPharma Holdings, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Matinas BioPharma Holdings, Inc. shares.
-
What Is The Matinas BioPharma Holdings, Inc. Share Price Today?
Matinas BioPharma Holdings, Inc. was last trading at $0.78 per share. This represents the most recent stock quote for Matinas BioPharma Holdings, Inc.. Yesterday, Matinas BioPharma Holdings, Inc. closed at $0.79 per share.
-
How To Buy Matinas BioPharma Holdings, Inc. Stock Online?
In order to purchase Matinas BioPharma Holdings, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MTNB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MTNB
Sector
P/E ratio
--
23.75x
PEG ratio
--
-0.01x
P/B ratio
0.78x
1.83x
Price / LTM sales
1.74x
1.60x
Growth Metrics
MTNB
Sector
Revenue growth
--
4.85%
Earnings growth
53.39%
11.11%
Revenue (5-year growth)
-100%
6.45%
Earnings forecast
-$0.78
-$0.20
Profitability
MTNB
Sector
Profitability FY 2024
-$972K
$3.6M
Return on invested capital
-152.52%
-30.98%
Return on assets
-131.71%
-27.62%
Return on equity
-199.71%
-36.69%
Earnings Date
Last Earnings Date
Aug
13
Next Earnings Date
Dec
8
Estimated Next Earnings Date
Mar
9
Balance Sheet
MTNB
Sector
Total cash
$5.5M
$27.2M
Short term investments
--
$25.7M
Total assets
$12.6M
$79.7M
Long term debt
$1.5M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
